{"id":45255,"date":"2022-12-15T00:02:41","date_gmt":"2022-12-15T05:02:41","guid":{"rendered":"https:\/\/reviewofmm.com\/?p=45255"},"modified":"2022-12-13T12:45:57","modified_gmt":"2022-12-13T17:45:57","slug":"johnson-johnson-vision-at-the-forefront-of-myopia-research-at-the-international-myopia-conference-2022","status":"publish","type":"post","link":"https:\/\/reviewofmm.com\/johnson-johnson-vision-at-the-forefront-of-myopia-research-at-the-international-myopia-conference-2022\/","title":{"rendered":"Johnson & Johnson Vision at the Forefront of Myopia Research at the International Myopia Conference 2022"},"content":{"rendered":"
sponsored content<\/p>\n
December 15, 2022<\/strong><\/p>\n By Monica Jong, PhD, BOptom,<\/strong> Noel Brennan, MScOptom, PhD, FAAO,<\/strong> Xu Cheng, MD, PhD, MBA, FAAO, and<\/strong> Alex Nixon, OD, MS, FAAO<\/strong><\/b><\/p>\n Johnson & Johnson Vision is committed to leading by science to change the trajectory of myopia, helping give children clearer vision today, for better eye health tomorrow.<\/span><\/p><\/blockquote>\n <\/p>\n The Johnson & Johnson Vision<\/a> team recently presented their latest innovative research at the International Myopia Conference (IMC) in Rotterdam, The Netherlands, which took place September 4-7, 2022. This meeting last took place in 2019 and has a tradition of bringing together leading scientists and experts in the field. The IMC is the largest and most prestigious international myopia meeting, showcasing the latest research in epidemiology, mechanisms, experimental, and clinical trial studies. This year more than 700 delegates attended one of the biggest IMCs to date.<\/span><\/p>\n Johnson & Johnson Vision presented 12 posters and podium presentations. A major highlight of the IMC was the presentation of never-before-seen technology and clinical results behind a breakthrough soft contact lens for myopia management by Dr. Monica Jong, Dr. Xu Cheng, Dr. Noel Brennan, and Lisa McAlister to a standing-room-only crowd. The engaging session brought together attendees from all around the world and discussed impactful ways to address the growing myopia epidemic.\u00a0\u00a0<\/span><\/p>\n Johnson & Johnson Vision is committed to leading by science to change the trajectory of myopia, helping give children clearer vision today, for better eye health tomorrow.<\/span><\/p>\n Below we have summarized several of the most exciting IMC research presented by Johnson & Johnson Vision<\/span> exploring the mechanisms of myopia and the technology behind a breakthrough soft contact lens designed for myopia control, specifically for pediatric eyes.\u00a0<\/span><\/p>\n Adult Myopia and Its Implications to Myopia Prevalence Around the World<\/b>1<\/sup> These four clinical studies demonstrate that myopia progression occurs in adults, beyond the teenage years through to age 50 by an average of about 1.00D or more. If we use late teenage myopia prevalence rates, we may be underestimating the comorbidity of myopia in our current myopia disease prevalence predictions.\u00a0<\/span><\/p>\n Investigating Myopia Control Using ChromaBlur<\/b>6<\/sup> Optical Soft Contact Lens Designs for Myopia Control<\/b>8<\/sup> Pediatric Fit and Performance of Various Soft Contact Lens Prototypes and the Preferred Design<\/b>10 Impact of Soft Contact Lens Design on Ease of Handling and Comfort in Myopic Children<\/b>12<\/sup> <\/p>\n
\n<\/b>There are limited studies on adult myopia progression, and greater understanding is important for better clinical management. Four<\/span> long-term studies were reviewed, and refractive progression rates were calculated for adults aged 20 to 50 years. Using data from Vitale et al.<\/span>2<\/span><\/sup> on a U.S. adult population between 1971-72 and 1999-2004, calculated progression rates over a period of 28 years were higher for higher degrees of myopic refractive error. Data from Goldblum et al.<\/span>3<\/span><\/sup> over five to 10 years suggested that myopia progression was similar among varying degrees of myopia in a German population. Calculated prevalence rates were not possible with data from Ducloux et al.<\/span>4<\/span><\/sup> However, a trend of myopia progression reducing with increasing age could be considered in the French population. Calculated progression rates with five-year data from Takeuchi et al.<\/span>5<\/span><\/sup> surprisingly found that Japanese adult males progressed faster than adult females, and those with lower degrees of myopia also progressed more quickly.\u00a0<\/span><\/p>\n
\n<\/b>Can the use of chromatic fringes in an image, known as \u201cChromaBlur (CB),\u201d help us to better understand how the retina detects the sign of defocus and alters eye growth?<\/span> It has been demonstrated by Cholewiak et al.<\/span>7<\/span><\/sup> that CB can drive accommodation and depth perception. To investigate the effects of CB on short-term axial length change (a putative biomarker for long-term refractive development), 20 subjects (aged 20-35 years) were asked to watch a 40-minute movie with CB. Axial length and accommodation were measured at 10-minute intervals. This investigation found that accommodation was stimulated by CB. However, it was very small, and axial length did not significantly change within the 40 minutes of ChromaBlur exposure as compared to exposure to 40 minutes of optically induced blur.<\/span><\/p>\n
\n<\/b>Traditionally, soft myopia control contact lenses have been limited by treatment power versus vision quality.<\/span> Enhancing the efficacy of soft contact lenses for myopia control requires disrupting this relationship. A<\/span>n optimized myopia control lens was designed using sophisticated optical modelling as well as an empirical purpose-built optical table consisting of biometric (axial length) measurement, spatial light modulator to deliver optical stimuli, pupil tracking, VA, contrast sensitivity and halo measurements. This lens design comprised a conic section of a torus as the optics of the myopia control treatment zone, overcoming the need to bring the light in the treatment zone to a point focus. The use of non-coaxial<\/i><\/b> plus power in the treatment zone substantially reduced the ghosting and shadowing artifacts while retaining the myopia control properties. A six-month masked, randomized, controlled clinical trial confirms this finding. As a result, this soft contact lens, which was designed to break the interdependency<\/i><\/b> between efficacy for slowing the progression of myopia and providing similar visual quality to a classic dual focus design,9<\/sup> was granted Breakthrough Device designation<\/a> by the U.S. FDA to provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.*<\/p>\n
\n<\/b><\/sup>To optimize fit and handling of a myopia control soft contact lens for pediatrics, ocular biometric characteristics of 300 Chinese children were assessed. This research found reduced Horizontal Eyelid Fissure (HEF) and Palpebral Aperture (PA) compared to adults,<\/span>11<\/span><\/sup> leading to prototype soft contact lens designs with diameters ranging from 13.6 to 14.0 mm, base curves ranging from 7.9 and 8.5 mm with a shape factor of 0.26. These various contact lens parameters were then assessed for performance preference. An aspheric design, 13.8 mm diameter and 7.9 mm BC provided optimal centration, movement, and minimal corneal limbal exposure compared to other designs tested. In a trial of a soft contact lens with RingBoost optical design (n=199, age 7 to 12 years), there were no instances of unacceptable lens fittings. At the initial fitting, 94.7% reported centered fit, and 88.2% had optimal movement. At the one-month review, 93% agreed the lens was easy to insert, and 95% agreed it was easy to remove. This soft contact lens, specifically designed for pediatric use, demonstrated excellent fit and handling.\u00a0<\/span><\/p>\n
\n<\/span>Soft contact lens designs were assessed in a pediatric population for handling and comfort using the qualitatively valid Pediatric Comfort and Handling Questionnaire (PCHQ). A total of 75 myopic children aged 7 to 17 years were recruited across multiple sites and randomized to wear three sets of contact lenses bilaterally, including senofilcon A RingBoost Technology (RB), senofilcon A with prototype optics (PO), and the marketed omafilcon A dual focus design (DF). Both senofilcon A designs feature the same smaller diameter and steeper base curve, differing only in optical design. The order of lens wear was randomized, and each design was worn for two weeks, with the questionnaire completed via a digital device after fitting and at the two-week follow-up. The greatest difference in the proportion of \u201cgood\u201d responses for the various contact lenses was in the insertion, comfort, and comfort-related compensating behavior constructs. At follow-up, the senofilcon A RB and PO designs had similar proportion of \u201cgood\u201d responses; however, RB and PO exceeded the omafilcon A DF design by 15% across five of the six insertion-related items and several comfort and compensating behavior items. In a pediatric population, the senofilcon A lenses with a smaller diameter and steeper base curve provided a higher proportion of good responses for insertion and comfort than the omafilcon a dual focus lens. A larger study would provide a more definitive conclusion.\u00a0<\/span><\/p>\n